Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial

Elshamy, Maged; Gibreel, Ahmed; Refai, E.; Sadek, Ehab E.

doi:10.1016/j.mefs.2011.11.005

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anastrozole or letrozole were shown to reduce endometrial thickness in patients with EH [ 169 ]. Recent studies have established letrozole as good therapeutic option for simple EH without atypia [ 170 171 ]. Anastrozole was also found to be an interesting new modality for the treatment of EH in obese postmenopausal women [ 172 ].…”

Section: Limitations Of Existing Therapies Need For Further Researchmentioning

confidence: 99%

Therapeutic options for management of endometrial hyperplasia

et al. 2016

View full text Add to dashboard Cite

Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.

show abstract

Section: Limitations Of Existing Therapies Need For Further Researchmentioning

confidence: 99%

Therapeutic options for management of endometrial hyperplasia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In view of its ability to suppress ovulation and reduce the endometrial lining, it has been recommended as a long term alternative to combined oral contraceptive and laparoscopic surgery for those women with endometriosis who do not consider getting pregnant [63]. Aromatase inhibitor is found to be as effective as the Norethindrone acetate in treating endometriosis but the estrogen level is lower and the endometrial lining is thinner in women taking Letrozole [64].…”

Section: Comparing Aromatase Inhibitor With Other Treatment Optionsmentioning

confidence: 99%